308 related articles for article (PubMed ID: 23896378)
41. NMR-based metabolomic techniques identify potential urinary biomarkers for early colorectal cancer detection.
Wang Z; Lin Y; Liang J; Huang Y; Ma C; Liu X; Yang J
Oncotarget; 2017 Dec; 8(62):105819-105831. PubMed ID: 29285295
[TBL] [Abstract][Full Text] [Related]
42. Identifying the Metabolic Signatures of PPARD-Overexpressing Gastric Tumors.
Pudakalakatti S; Titus M; Enriquez JS; Ramachandran S; Zacharias NM; Shureiqi I; Liu Y; Yao JC; Zuo X; Bhattacharya PK
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163565
[TBL] [Abstract][Full Text] [Related]
43. Metabolomics study of oral cancers.
Chen X; Yu D
Metabolomics; 2019 Feb; 15(2):22. PubMed ID: 30830419
[TBL] [Abstract][Full Text] [Related]
44. Metabolomics-A Promising Approach to Pituitary Adenomas.
Pînzariu O; Georgescu B; Georgescu CE
Front Endocrinol (Lausanne); 2018; 9():814. PubMed ID: 30705668
[No Abstract] [Full Text] [Related]
45. NMR-derived targeted serum metabolic biomarkers appraisal of bladder cancer: A pre- and post-operative evaluation.
Gupta A; Bansal N; Mitash N; Kumar D; Kumar M; Sankhwar SN; Mandhani A; Singh UP
J Pharm Biomed Anal; 2020 May; 183():113134. PubMed ID: 32070930
[TBL] [Abstract][Full Text] [Related]
46. Biomarkers in bladder cancer: A metabolomic approach using in vitro and ex vivo model systems.
Rodrigues D; Jerónimo C; Henrique R; Belo L; de Lourdes Bastos M; de Pinho PG; Carvalho M
Int J Cancer; 2016 Jul; 139(2):256-68. PubMed ID: 26804544
[TBL] [Abstract][Full Text] [Related]
47. A plasma metabolomic signature discloses human breast cancer.
Jové M; Collado R; Quiles JL; Ramírez-Tortosa MC; Sol J; Ruiz-Sanjuan M; Fernandez M; de la Torre Cabrera C; Ramírez-Tortosa C; Granados-Principal S; Sánchez-Rovira P; Pamplona R
Oncotarget; 2017 Mar; 8(12):19522-19533. PubMed ID: 28076849
[TBL] [Abstract][Full Text] [Related]
48. Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer.
Ikeda A; Nishiumi S; Shinohara M; Yoshie T; Hatano N; Okuno T; Bamba T; Fukusaki E; Takenawa T; Azuma T; Yoshida M
Biomed Chromatogr; 2012 May; 26(5):548-58. PubMed ID: 21773981
[TBL] [Abstract][Full Text] [Related]
49. Global serum metabolomics profiling of colorectal cancer.
Hashim NAA; Ab-Rahim S; Suddin LS; Saman MSA; Mazlan M
Mol Clin Oncol; 2019 Jul; 11(1):3-14. PubMed ID: 31289671
[TBL] [Abstract][Full Text] [Related]
50. Fecal and urinary NMR-based metabolomics unveil an aging signature in mice.
Calvani R; Brasili E; Praticò G; Capuani G; Tomassini A; Marini F; Sciubba F; Finamore A; Roselli M; Marzetti E; Miccheli A
Exp Gerontol; 2014 Jan; 49():5-11. PubMed ID: 24184118
[TBL] [Abstract][Full Text] [Related]
51. Current Trends in Cancer Biomarker Discovery Using Urinary Metabolomics: Achievements and New Challenges.
Burton C; Ma Y
Curr Med Chem; 2019; 26(1):5-28. PubMed ID: 28914192
[TBL] [Abstract][Full Text] [Related]
52. Metabolomic study for diagnostic model of oesophageal cancer using gas chromatography/mass spectrometry.
Wu H; Xue R; Lu C; Deng C; Liu T; Zeng H; Wang Q; Shen X
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Oct; 877(27):3111-7. PubMed ID: 19716777
[TBL] [Abstract][Full Text] [Related]
53. Metabolomic Profiling of Human Spermatozoa in Idiopathic Asthenozoospermia Patients Using Gas Chromatography-Mass Spectrometry.
Zhao K; Zhang J; Xu Z; Xu Y; Xu A; Chen W; Miao C; Liu S; Wang Z; Jia R
Biomed Res Int; 2018; 2018():8327506. PubMed ID: 29682560
[TBL] [Abstract][Full Text] [Related]
54. Metabolite signature of human malignant thyroid tissue: A systematic review and meta-analysis.
Razavi SA; Khorsand B; Salehipour P; Hedayati M
Cancer Med; 2024 Apr; 13(8):e7184. PubMed ID: 38646957
[TBL] [Abstract][Full Text] [Related]
55. Toxic effects of chronic low-dose exposure of thioacetamide on rats based on NMR metabolic profiling.
Wei DD; Wang JS; Wang PR; Li MH; Yang MH; Kong LY
J Pharm Biomed Anal; 2014 Sep; 98():334-8. PubMed ID: 24996005
[TBL] [Abstract][Full Text] [Related]
56. Metabolomic profiling of human lung tumor tissues - nucleotide metabolism as a candidate for therapeutic interventions and biomarkers.
Moreno P; Jiménez-Jiménez C; Garrido-Rodríguez M; Calderón-Santiago M; Molina S; Lara-Chica M; Priego-Capote F; Salvatierra Á; Muñoz E; Calzado MA
Mol Oncol; 2018 Oct; 12(10):1778-1796. PubMed ID: 30099851
[TBL] [Abstract][Full Text] [Related]
57. An Overview on the Importance of Combining Complementary Analytical Platforms in Metabolomic Research.
Gonzalez-Dominguez A; Duran-Guerrero E; Fernandez-Recamales A; Lechuga-Sancho AM; Sayago A; Schwarz M; Segundo C; Gonzalez-Dominguez R
Curr Top Med Chem; 2017; 17(30):3289-3295. PubMed ID: 29231141
[TBL] [Abstract][Full Text] [Related]
58. Faecal calprotectin as a marker for oesophago-gastric cancer.
Vincent Z; Hornby S; Ball S; Sanders G; Ayling RM
Ann Clin Biochem; 2015 Nov; 52(Pt 6):660-4. PubMed ID: 25732128
[TBL] [Abstract][Full Text] [Related]
59. Biomarkers of response to therapy in oesophago-gastric cancer.
Fareed KR; Kaye P; Soomro IN; Ilyas M; Martin S; Parsons SL; Madhusudan S
Gut; 2009 Jan; 58(1):127-43. PubMed ID: 19091831
[TBL] [Abstract][Full Text] [Related]
60. Human plasma metabolomics for identifying differential metabolites and predicting molecular subtypes of breast cancer.
Fan Y; Zhou X; Xia TS; Chen Z; Li J; Liu Q; Alolga RN; Chen Y; Lai MD; Li P; Zhu W; Qi LW
Oncotarget; 2016 Mar; 7(9):9925-38. PubMed ID: 26848530
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
